{"id":765315,"date":"2023-06-22T06:33:08","date_gmt":"2023-06-22T10:33:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/"},"modified":"2023-06-22T06:33:08","modified_gmt":"2023-06-22T10:33:08","slug":"affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/","title":{"rendered":"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HEIDELBERG, Germany, June  22, 2023  (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort\u2019s appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023.<\/p>\n<p align=\"justify\">\u201cWe are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board,\u201d said Dr. Thomas Hecht, Chairman of Affimed\u2019s Supervisory Board. \u201cConstanze brings a wealth of legal expertise and a deep understanding of the biotech and healthcare industries, making her an invaluable addition to our team. With her extensive background, we expect Constanze will provide critical insights and guidance to the Company on matters related to corporate governance, corporate strategy, compliance and ESG, among others.\u201d<\/p>\n<p align=\"justify\">Dr. Ulmer-Eilfort is a partner at the law firm Peters, Sch\u00f6nberger &amp; Partner, an interdisciplinary law and advisory firm located in Munich, Germany, a role she has held since 2022. Prior to that,\u00a0Dr.\u00a0Ulmer-Eilfort worked at Baker McKenzie serving in several roles, including as partner from 1998 to 2021, Member of the Global Executive Committee from 2017 to 2021, and as Managing Partner of the German and Austrian offices from 2012 to 2017.<\/p>\n<p align=\"justify\">Since 2021, Dr. Ulmer-Eilfort has served as member of the supervisory board of Evotec SE, a Hamburg-based, publicly listed drug discovery and development company. She also serves as Chair of the Advisory Committee at Smart4Diagnostics GmbH, a healthcare start-up based in Munich. Since 2022, Dr. Ulmer-Eilfort has also served as a member of the board of Proxygen GmbH, a Vienna based biotech company developing and commercializing molecular glue degraders, and is an advisor to the management board of Artidis AG, a Basel healthcare company developing a technology platform for the rapid diagnosis of cancer.<\/p>\n<p align=\"justify\">Dr.\u00a0Ulmer-Eilfort holds a law degree from the University of Munich, a Masters of Law degree from the University of Pennsylvania Law School, and a doctorate degree in law from the University of Berlin.<\/p>\n<p>\n        <strong>About Affimed N.V.<\/strong>\n      <\/p>\n<p align=\"justify\">Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company\u2019s proprietary ROCK<sup>\u00ae<\/sup> platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK<sup>\u00ae<\/sup> platform predictably generates customized innate cell engager (ICE<sup>\u00ae<\/sup>) molecules, which use patients\u2019 immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE<sup>\u00ae<\/sup>. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients\u2019 lives. For more about the Company\u2019s people, pipeline and partners, please visit: www.affimed.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook forward to,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions. Actual results may differ materially from the results anticipated by the Company\u2019s forward-looking statements due to certain risks, uncertainties and other factors described under the heading \u201cRisk Factors\u201d in Affimed\u2019s filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong>\n      <\/p>\n<p>Alexander Fudukidis<br \/>Director, Investor Relations<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_K9BnEMcf9dvyaNeQbWAespFfDGm4yGydfvSoRb-b0tmjyQ_guVN9nOR2PAkMbCDj3ESqeb0ht58PCrPBr688uuiENJNgV6sI8AtWHFhh9E=\" rel=\"nofollow noopener\" target=\"_blank\">a.fudukidis@affimed.com<\/a><\/p>\n<p>Tel.: +1 (917) 436-8102<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTU5MDc0YTUtOWNkMS00YjhkLWEwNzItNDg4MTE1YjJjMTA1LTEwMTUzMDc=\/tiny\/Affimed-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort\u2019s appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. \u201cWe are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board,\u201d said Dr. Thomas Hecht, Chairman of Affimed\u2019s Supervisory Board. \u201cConstanze brings a wealth of legal expertise and a deep understanding of the biotech and healthcare industries, making her an invaluable addition to our team. With her extensive background, we expect Constanze will provide critical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765315","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort\u2019s appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. \u201cWe are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board,\u201d said Dr. Thomas Hecht, Chairman of Affimed\u2019s Supervisory Board. \u201cConstanze brings a wealth of legal expertise and a deep understanding of the biotech and healthcare industries, making her an invaluable addition to our team. With her extensive background, we expect Constanze will provide critical &hellip; Continue reading &quot;Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T10:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board\",\"datePublished\":\"2023-06-22T10:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/\"},\"wordCount\":630,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/\",\"name\":\"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=\",\"datePublished\":\"2023-06-22T10:33:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/","og_locale":"en_US","og_type":"article","og_title":"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board - Market Newsdesk","og_description":"HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort\u2019s appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. \u201cWe are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board,\u201d said Dr. Thomas Hecht, Chairman of Affimed\u2019s Supervisory Board. \u201cConstanze brings a wealth of legal expertise and a deep understanding of the biotech and healthcare industries, making her an invaluable addition to our team. With her extensive background, we expect Constanze will provide critical &hellip; Continue reading \"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-22T10:33:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board","datePublished":"2023-06-22T10:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/"},"wordCount":630,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/","name":"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=","datePublished":"2023-06-22T10:33:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjMxNyM1NjU4NzM4IzIwMDM3MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-announces-addition-of-dr-constanze-ulmer-eilfort-to-its-supervisory-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765315"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765315\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}